Gencurix Inc. (KOSDAQ:229000)
South Korea · Delayed Price · Currency is KRW 1,536.00
-29.00 (-1.85%)
Sep 19, 2025, 3:30 PM KST
Gencurix Revenue
Gencurix had revenue of 1.44B KRW in the quarter ending September 30, 2024, with 50.03% growth. This brings the company's revenue in the last twelve months to 3.39B, up 25.69% year-over-year. In the year 2023, Gencurix had annual revenue of 2.60B with 1.60% growth.
Revenue (ttm)
3.39B
Revenue Growth
+25.69%
P/S Ratio
7.30
Revenue / Employee
n/a
Employees
n/a
Market Cap
24.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 2.60B | 40.83M | 1.60% |
| Dec 31, 2022 | 2.56B | -487.46M | -16.00% |
| Dec 31, 2021 | 3.05B | 1.47B | 93.83% |
| Dec 31, 2020 | 1.57B | 1.44B | 1,050.64% |
| Dec 31, 2019 | 136.62M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,031.69B |
| Celltrion | 3,748.95B |
| ALTEOGEN | 158.06B |
| Yuhan | 2,165.44B |
| SK Biopharmaceuticals | 620.28B |
| Peptron | 5.18B |
| PharmaResearch | 449.81B |
| ABL Bio | 94.93B |
Gencurix News
- 3 months ago - Qiagen and Gencurix partner for oncology tests - Seeking Alpha